Instrument Inactif

Communiqués Qiagen NV Nasdaq

Actions

NL0000240000

Recherche biotechnologique et médicale

Communiqués

06/10	QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery	BU
28/09	QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel	BU
24/09	QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation	BU
21/09	QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board	AQ
18/09	QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board	BU
28/08	10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences	PR
27/08	QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction	BU
24/08	QIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer	BU
24/08	QIAGEN N.V.: QIAGEN appoints Jonathan M. Pratt as Chief Executive Officer	EQ
21/08	Qiagen N : 2026 Annual Report 2026 IFRS Half Year Report	PU
20/08	Qiagen N : BlackRock Inc. - Qiagen N.V. - VENLO	PU
20/08	Qiagen N : Wellington Management Group LLP - Qiagen N.V. - VENLO	PU
13/08	Qiagen N : Bank of America Corporation - Qiagen N.V. - VENLO	PU
13/08	Qiagen N : Wellington Management Group LLP - Qiagen N.V. - VENLO	PU
10/08	QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel	BU
05/08	Qiagen: Q2 Earnings Snapshot	AQ
05/08	QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook	BU
16/07	QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe	AQ
15/07	QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak	BU
15/07	QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast	BU
14/07	QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe	BU
07/07	Qiagen N : announces adjustment of conversion price under its US$500,000,000 Convertible Bonds due 2031	PU
07/07	Qiagen N : announces adjustment of conversion price under its US$750,000,000 Convertible Bonds due 2032	PU
07/07	Qiagen N : announces adjustment of conversion price under its US$500,000,000 Convertible Bonds due 2027	PU
25/06	Qiagen N : Sustainability Report (ca ab 1305 voluntary carbon market disclosure 2026)	PU